Eli Lilly & Co.'s SEC filings document the regulatory record for its pharmaceutical business, listed common stock and NYSE-traded notes. Forms 8-K report operating results and financial condition, annual meeting vote outcomes, director and officer matters, underwriting agreements and other material events tied to the company's capital structure and governance.
Proxy filings provide formal disclosure on board elections, executive compensation, shareholder voting matters and pay-versus-performance information. The company's exchange-listed securities include no-par common stock under LLY and multiple series of notes with maturities extending across its debt capital structure.
Eli Lilly executive insider filing shows a corrected share adjustment. On February 9, 2026, the reporting officer (EVP & CIDO) is shown as having acquired 4,599.164 shares of Eli Lilly common stock at $1,044.67 per share. After this adjustment, the executive directly owns 26,396.534 shares. The accompanying note explains this amended Form 4 corrects an earlier over-withholding of shares for tax obligations caused by an administrative error.
Eli Lilly and Company filed its annual report for the year ended December 31, 2025, outlining a global human pharmaceuticals business focused on cardiometabolic health, oncology, immunology, and neuroscience. Key growth drivers include diabetes, obesity, cardiovascular, cancer, immunology, and migraine/Alzheimer’s medicines such as Mounjaro/Zepbound, Trulicity, Jardiance, Verzenio, Omvoh, Taltz, Emgality, and Kisunla.
The company highlights extensive patent and data exclusivity across major products, with key expiries stretching into the 2030s and 2040s, and notes heavy reliance on intellectual property protection. It details a complex regulatory environment across the U.S., EU, Japan, China, and other markets, including the impact of biosimilars, generics, compounding and counterfeit incretin products, and evolving FDA, EMA, and other oversight.
Lilly discusses significant pricing and reimbursement pressures, including the U.S. Inflation Reduction Act, 340B dynamics, and an announced preliminary voluntary agreement with the U.S. government to lower certain prices and expand access, especially for obesity medicines. The report also describes large manufacturing capacity expansions globally, a 50,000-person workforce with 12,000 in R&D, and an experienced executive team. Shares of common stock outstanding were 943,357,420 as of February 9, 2026.
Eli Lilly & Co senior vice president, finance, and chief accounting officer Donald A. Zakrowski acquired additional company equity on February 9, 2026. He received 583.784 shares of common stock as a grant or award at $1,044.67 per share, bringing his directly held common stock to 3,423.443 shares.
He also received a grant of 199.472 restricted stock units, each representing a contingent right to one share of common stock, with both exercisable and expiration dates of February 16, 2029. In addition, 1,728.57 common shares are held indirectly through a 401(k) plan.
Eli Lilly executive Ilya Yuffa reported an acquisition of company stock through an equity award. On 02/09/2026, he received 4,162.504 shares of Eli Lilly common stock in a grant or other acquisition at a price of $1,044.67 per share. Following this award, he directly holds 32,304.111 shares of Eli Lilly common stock as EVP & President, LLY USA & Global Capabilities.
Eli Lilly executive Jacob Van Naarden, EVP and President of LLY Oncology & Head of Corporate Business Development, acquired 4,865.888 shares of Eli Lilly common stock on February 9, 2026 through a grant or award at $1,044.67 per share. Following this award, he directly holds 26,626.498 common shares. He also has indirect holdings of 4,342 shares through the Van Naarden Family Trust and 5,302 shares through a spousal lifetime access trust. The transactions are reported with a disclaimer that he only beneficially owns the securities to the extent of his pecuniary interest, and a footnote explains a February 5, 2026 transfer of 5,302 spouse-held shares into the spousal lifetime access trust, including 1,000 shares previously misreported as directly held.
Eli Lilly & Co. executive Daniel Skovronsky reported an acquisition of company common stock through a grant or award. On 02/09/2026, he received 15,547.862 shares at a price of $1,044.67 per share, bringing his directly held stake to 160,071.725 shares, with additional indirect holdings through a trust and spouse-related entities.
Ricks David A reported acquisition or exercise transactions in this Form 4 filing.
Eli Lilly & Co President, Chair, CEO and director David A. Ricks received a grant of 38,913.584 shares of common stock on February 9, 2026 at $1,044.67 per share. Following this award, he directly held 571,715.097 common shares.
He also reported indirect holdings through several vehicles, including the David A. Ricks 2025 GRAT, the David A. Ricks 2022 GRAT, a trust, the David A. Ricks SLAT, and a 401(k) account, while disclaiming beneficial ownership except to the extent of his pecuniary interest.
Eli Lilly executive Diogo Rau reported an equity award in company stock. On 02/09/2026, the EVP & CIDO acquired 4,432.32 shares of Eli Lilly common stock through a grant or award at a price of $1,044.67 per share. Following this transaction, Rau directly beneficially owned 26,229.69 shares of Eli Lilly common stock.
Montarce Lucas reported acquisition or exercise transactions in this Form 4 filing.
Eli Lilly & Co. executive vice president and chief financial officer Lucas Montarce reported receiving a stock award of 1,365.47 shares of common stock on February 9, 2026. The award was recorded at a price of $1,044.67 per share, bringing his directly held stake to 16,050.206 shares.
Eli Lilly executive Patrik Jonsson, EVP & President, LLY International, reported an acquisition of company stock through an equity award. On 02/09/2026 he received 4,818.052 shares of common stock at $1,044.67 per share, bringing his directly held stake to 60,646.62 shares, with additional indirect holdings in a 401(k) plan.